vs
Side-by-side financial comparison of Dexcom (DXCM) and WEIBO Corp (WB). Click either name above to swap in a different company.
WEIBO Corp is the larger business by last-quarter revenue ($1.3B vs $1.3B, roughly 1.0× Dexcom). WEIBO Corp runs the higher net margin — 35.7% vs 21.2%, a 14.5% gap on every dollar of revenue. Over the past eight quarters, WEIBO Corp's revenue compounded faster (22.6% CAGR vs 12.0%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
DXCM vs WB — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $1.3B |
| Net Profit | $267.3M | $458.3M |
| Gross Margin | 62.9% | — |
| Operating Margin | 25.6% | 29.1% |
| Net Margin | 21.2% | 35.7% |
| Revenue YoY | 21.6% | — |
| Net Profit YoY | 153.6% | — |
| EPS (diluted) | $0.67 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.2B | $1.3B | ||
| Q2 25 | $1.2B | $841.7M | ||
| Q1 25 | $1.0B | $396.9M | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $994.2M | $1.3B | ||
| Q2 24 | $1.0B | $833.4M |
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | — | ||
| Q3 25 | $283.8M | $458.3M | ||
| Q2 25 | $179.8M | $234.8M | ||
| Q1 25 | $105.4M | $108.1M | ||
| Q4 24 | $151.7M | — | ||
| Q3 24 | $134.6M | $297.4M | ||
| Q2 24 | $143.5M | $164.6M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | — | ||
| Q3 25 | 60.5% | — | ||
| Q2 25 | 59.5% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | — | ||
| Q3 24 | 59.7% | — | ||
| Q2 24 | 62.4% | — |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | — | ||
| Q3 25 | 20.1% | 29.1% | ||
| Q2 25 | 18.4% | 30.4% | ||
| Q1 25 | 12.9% | 27.8% | ||
| Q4 24 | 17.0% | — | ||
| Q3 24 | 15.3% | 29.0% | ||
| Q2 24 | 15.7% | 28.2% |
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | — | ||
| Q3 25 | 23.5% | 35.7% | ||
| Q2 25 | 15.5% | 27.9% | ||
| Q1 25 | 10.2% | 27.2% | ||
| Q4 24 | 13.6% | — | ||
| Q3 24 | 13.5% | 22.9% | ||
| Q2 24 | 14.3% | 19.8% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | — | ||
| Q3 25 | $0.70 | — | ||
| Q2 25 | $0.45 | — | ||
| Q1 25 | $0.27 | — | ||
| Q4 24 | $0.37 | — | ||
| Q3 24 | $0.34 | — | ||
| Q2 24 | $0.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $3.9B |
| Total Assets | $6.3B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | — | ||
| Q3 25 | $1.8B | $1.1B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $904.9M | $1.2B | ||
| Q4 24 | $606.1M | — | ||
| Q3 24 | $621.2M | — | ||
| Q2 24 | $939.2M | $1.9B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.7B | $3.9B | ||
| Q2 25 | $2.6B | $3.6B | ||
| Q1 25 | $2.3B | $3.5B | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.4B | $3.4B |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $7.5B | $6.9B | ||
| Q2 25 | $7.3B | $6.5B | ||
| Q1 25 | $6.8B | $6.7B | ||
| Q4 24 | $6.5B | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.8B | $7.1B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXCM
Segment breakdown not available.
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
